Clinical Recognition and Treatment of Levodopa-Induced Dyskinesia

Levodopa-Induced Dyskinesia Introduction

Prevalence of Dyskinesia

Videos: Disordered Movement Types

Fluctuations in Dopamine Levels

Dysregulation of Dopamine Leading to the Development of Dyskinesia

Effects of AEs on Patient Quality of Life

Patient-Rated Impairment in Quality of Life

Rating Scales Used to Assess Dyskinesia

Approaches to Levodopa-Induced Dyskinesia Management

Amantadine IR

Amantadine ER Overview of Clinical Studies

Primary Endpoint: UDysRS Results Over Time EASE LID and EASE LID 3

Key Secondary Endpoints: Home Diary Data EASE LID and EASE LID 3

Most Common AEs and Reasons for Treatment Discontinuation Amantadine ER

Additional Approaches

Concluding Remarks

Abbreviations